Fig. 1: EPA administration impaired learning and memory and hippocampal LTP in adult mice (P60).
From: Acute EPA-induced learning and memory impairment in mice is prevented by DHA
a, b Mean escape latencies across 4 consecutive days (a) or on the last day (b) during the MWM training (n = 9–11 mice/group; a: repeated measures two-way ANOVA, F(4, 180) = 55.518, P < 0.0001; b: one-way ANOVA, F(4, 47) = 54.568, P = 0.003; asterisk, triangle or hash indicates differences between EPA [50], EPA [75] or EPA [150] and Ctrl [saline-treated], respectively). c, d Percentage of distance (c) or time (d) spent in target quadrant during the probe trials (one-way ANOVA; c: F(4, 47) = 43.806, P = 0.016; d: F(4, 47) = 43.381, P = 0.018). e Number of platform crossings during the probe trials (one-way ANOVA; F(4, 47) = 45.431, P = 0.002). f Freezing time in the contextual fear conditioning test (n = 10–12 mice/group; one-way ANOVA; F(4, 50) = 48.636, P < 0.0001). g Discrimination ratio of time spent interacting with a novel object versus a familiar object in the NOR test (50 mg/kg, n = 10 mice/group; two-tailed Student’s t-test; P < 0.0001). h I.g. administration of 50 mg/kg EPA increased the EPA level in the hippocampus (detected at 1 h after EPA administration; n = 8; two-tailed Student’s t-test; P = 0.001). i, j I.g. administration of EPA suppressed HFS-induced LTP (recorded at 2 h after EPA administration; n = 5–7 slices/group; one-way ANOVA; F(4, 26) = 52.545, P < 0.0001). k–n Acute EPA treatment 10 min after establishing the baseline recording impaired HFS-LTP (k, l, n = 5–14 slices/group; one-way ANOVA; F(3, 35) = 47.807, P < 0.0001) and TBS-LTP (m, n, n = 7–8 slices/group; two-tailed Student’s t-test; P < 0.0001). Scale bars: 0.5 mV, 5 ms. Data show mean ± s.e.m.. *P < 0.05, **P < 0.01, ***P < 0.001.
